Want to see ILMN full AI Analyst Report?
ILMN Stock Chart & Stats
$134.50
-$1.43(-1.02%)
At close: 4:00 PM EST
$134.50
-$1.43(-1.02%)
Day’s Range― - ―
52-Week Range$88.00 - $196.66
Previous CloseN/A
Volume388.94K
Average Volume (3M)2.05M
Market Cap
$28.78B
Enterprise Value$25.53B
Total Cash (Recent Filing)$1.16B
Total Debt (Recent Filing)$2.54B
Price to Earnings (P/E)34.3
Beta1.23
Next Earnings
Jul 30, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.54
Shares Outstanding151,300,000
10 Day Avg. Volume1,848,323
30 Day Avg. Volume2,045,837
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue5.81
Enterprise Value/Gross Profit8.59
Enterprise Value/Ebitda18.13
Forecast
1Y Price Target
$162.14Price Target Upside20.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)5.23
Revenue Forecast (FY)$4.57B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationIllumina’s high and consistent cash generation (operating cash flow ~$1.13B, FCF ~$0.99B) provides durable funding for R&D, capacity buildouts, M&A, and buybacks. Strong FCF conversion (~88% of net income) improves resilience through research funding cycles and supports strategic investments without tapping fragile liquidity.
Rebounded Profitability And MarginsA meaningful margin recovery to mid/high-60s gross and ~22% operating margin reflects improved cost structure and a higher-margin product mix (consumables and clinical revenue). Durable margin expansion enhances free cash flow potential and provides buffer against cyclical top-line weakness while enabling sustained investment in product roadmap.
Installed-base Transition To NovaSeq XRapid NovaSeq X adoption (>80 placements; 82% of volumes on X) accelerates recurring consumables pull-through and creates a durable competitive moat via platform lock-in. Higher throughput and clinical adoption increase consumables cadence and mix, structurally supporting recurring revenue and long-term margin durability versus instrument-led spikes.
Bears Say
Research & Applied Consumables WeaknessA persistent decline in research & applied consumables (‑12% ex‑China) signals secular pressure from constrained academic and grant-funded spending. Because consumables are the recurring revenue core, softer research demand can cap top-line growth for several quarters and delay realization of installed-base conversion benefits.
Microarrays Business DeclineA ~20% RoW organic drop in microarrays reflects loss of specific large customers and secular weakness in that end-market. This contraction reduces product diversification and recurring revenue streams, increasing reliance on sequencing consumables and amplifying downside if other end markets underperform.
Mixed Balance Sheet And Reduced Equity CushionAlthough leverage has improved, debt at ~0.8x equity and materially lower equity versus 2022–2023 reduces the capital cushion. That weaker balance-sheet headroom raises sensitivity to earnings volatility and may constrain large-scale capital deployment or increase borrowing costs if market conditions deteriorate.
Illumina News
ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was $88.00 and its highest was $196.66 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is $28.78B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Jul 30, 2026 which is in 15 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Apr 30, 2026. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.055 by $0.095.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.23.
How many shares outstanding does Illumina have?
Illumina has 151,300,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of $1.15 in its last earnings report, beating expectations of $1.055. Following the earnings report the stock price went up 7.133%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$162.14 (20.55% Upside)
$162.14 (20.55% Upside)
Blogger Sentiment
Bullish
ILMN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 789.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $146.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.48%
12-Months-Change
Fundamentals
Return on Equity
33.99%
Trailing 12-Months
Asset Growth
6.10%
Trailing 12-Months
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
ILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
ILMN Stock 12 Month Forecast
Average Price Target
$162.14
▲(20.55% Upside)
Technical Analysis
Ownership Overview
2.13% Insiders
28.21% Mutual Funds
0.25% Other Institutional Investors
46.13% Public Companies and Individual Investors